跳至主要内容
临床试验/NCT00761683
NCT00761683终止不适用

Non-Interventional Study to Evaluate Effect of Zoladex In EndometrioSIS

AstraZeneca1 个研究点 分布在 1 个国家目标入组 105 人开始时间: 2008年10月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
AstraZeneca
入组人数
105
试验地点
1
主要终点
Biberoglu and Bergham Scale

研究概览

简要总结

To observe the effect of goserelin 3,6mg sc depot injection by assessment of the mean percent reduction scores for symptoms: dysmenorrhoea, dyspareunia and pelvic pain; to observe the effect of goserelin 3,6mg sc depot injection by assessment of the mean percent reduction scores for pelvic tenderness and indurations; to observe the reduction in the proportion of patients requiring analgesics for the relief of pelvic pain for 6 months in patients treated with Zoladex 3.6 mg.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • patients diagnosed with endometriosis that the doctors have already decided to treat with Zoladex within the last month, before inclusion in this program, according to Romanian approved goserelin 3,6 mg

排除标准

  • patients who have a known hypersensitivity to goserelin (Zoladex) or any of its excipients or any other GnRH analogue, pregnancy, according to Romanian approved goserelin 3,6 mg SmPC

结局指标

主要结局

Biberoglu and Bergham Scale

时间窗: monthly/ at every clinic visit- 6 times for symptoms: dysmenorrhoea, dyspareunia and pelvic pain

次要结局

  • Biberoglu and Bergham Scale(twice/first and last clinic visit for pelvic tenderness and indurations)

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

Non-Interventional Study to Evaluate Effect of... | 临床试验